$ADNT

Adient plc (ADNT): Results of Operations and Financial Condition

Adient plc (ADNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a08052026adientexhibit991.htm EX-99.1 Document Exhibit 99.1 Appendix Page 1 Adient plc Condensed Consolidated Statements of Income (Loss) (Unaudited) Three Months Ended June 30, (in millions, except per share data) 2026 2025 Net sales $ 3,929 $ 3,741 Cost of sales 3,694

Original reporting
Published Aug 5, 2026, 10:54 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ADNT
Neutral
medium confidence
Mentioned
$ADNT
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ADNTNeutralMed
01

Why it matters

This filing updates the latest quarter’s profitability, leverage, and liquidity snapshot, which can affect near-term positioning for auto-parts and industrial value chains.

02

Market read

Traders can recalibrate expectations using the reported quarter’s net sales, margins, segment adjusted EBITDA, and cash provided by operating activities.

03

What to watch

Restructuring and impairment costs and pension-related items can distort comparability; traders may want to focus on adjusted EBITDA and free cash flow drivers rather than headline net income.

Relevance 7/10Novelty 6/10Timing: filed pre-market today (2026-08-05) with Q2 results

Background

The SEC 8-K reports Adient plc results of operations and financial condition for the three months ended June 30, 2026, including income statement, balance sheet, cash flow, and segment adjusted EBITDA.

Company-level read

Ticker impact

$ADNTNeutralMedium confidence
Context

Adient filed an 8-K with Q2 results showing net sales of $3,929 million and net income attributable to Adient of $25 million.

Expected impact

Likely modest, with focus on margin and cash generation versus prior-year quarter.

Evidence & confidence

The filing is a primary-source earnings update with GAAP income, segment adjusted EBITDA, and cash flow, but it does not include explicit guidance or a discrete surprise catalyst beyond the reported quarter.

Market effects

Auto-parts suppliers may see read-through on demand and cost discipline via segment adjusted EBITDA and restructuring/impairment levels.

Americas and Asia show higher adjusted EBITDA than prior year, while EMEA is mixed, informing regional demand expectations.

Limited broader macro signal; primarily company-specific financial condition and cash flow.

Counterpoint

Net income attributable to Adient fell to $25 million from $36 million year over year, which could offset any operating stability and pressure sentiment.

Key entities

  • Adient plc

    Issuer filing the 8-K with Q2 2026 financial results and condensed financial statements.

  • Americas, EMEA, Asia Pacific/China

    Reportable segments with adjusted EBITDA and net sales disclosed for the quarter.

Related articles

$ADNTMed

Adient misses earnings estimates despite stronger-than-expected revenue

Adient (NYSE:ADNT) reported Q3 adjusted EPS of $0.48, below the $0.57 consensus, while revenue rose to $3.93B versus a $3.7B forecast. The company cited about $32M in temporary headwinds and operational inefficiencies. Adient kept FY2026 guidance, expecting ~$15B revenue, and reported GAAP net income of $25M. Shares were down ~0.9% premarket.

$ADNTMedAI 8/10

Adient reports third quarter financial results; reaffirms earnings and FCF outlook for FY26

Adient (NYSE: ADNT) reported Q3 2026 results: GAAP net income of $25M and diluted EPS of $0.32, versus adjusted diluted EPS of $0.48. Adjusted EBITDA was $225M, roughly flat year over year despite about $32M of temporary headwinds. At June 30, 2026, gross debt was ~$2.4B, net debt ~$1.5B, and cash ~$924M. The company said it generated free cash flow and repurchased $30M of shares in Q3.

$ADNTLow

Adient plc (ADNT) Releases China Business Update

Adient plc (NYSE:ADNT) said in a May 20 China business update that since last year’s J.P. Morgan Summit it has received new bookings supporting sales growth. The company reported about $1.1 billion in annual business in FY2025 from four new auto brands, with ~70% from C-OEMs. It also noted a December 2025 JV via a 49% stake in SCI (Zhangjiakou) Co., Ltd.

$LLYMedAI 8/10

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly (LLY) reported Q2 U.S. revenue up 33% led by ZEPBOUND and MOUNJARO volume, while U.S. price fell 3% (9% excluding rebate and discount estimate changes). International revenue rose in constant currency, with MOUNJARO a key driver. Lilly raised its 2026 revenue outlook to $85B-$87B and guided non-GAAP EPS $35.50-$36.50. It also discussed Medicare GLP-1 coverage expansion and retatrutide Phase III results.

$BRK-BMed

Berkshire Hathaway Just Did Something It Hasn’t Done in More Than 3 Years

Berkshire Hathaway reported Q2 2026 cash and Treasury bills of $365.5 billion, down from $397.4 billion in Q1, ending a 14-quarter streak as a net seller. According to Berkshire, CEO Greg Abel became a net buyer of equities, adding about $20 billion net, and increased buybacks to $4.5 billion. Apple fell to 20% of the portfolio; Alphabet rose after a $10 billion investment.

$LIONMed

Lionsgate Studios Q1 Earnings Call Highlights

Lionsgate (NYSE:LION) Q1 earnings call said it expects downstream revenue from films through fiscal 2027 and that The Hunger Games: Sunrise on the Reaping could support later-year results. Television revenue was $189 million, segment profit $10 million. Trailing 12-month library revenue was $987 million, backlog $1.5 billion. Net debt fell $121 million to about $1.5 billion; leverage improved to 4.3x.